|
Title
|
|
|
|
**In vitro** profiling of pramiconazole and in vivo evaluation in **Microsporum canis** dermatitis and Candida albicans vaginitis laboratory models
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| The triazole antifungal pramiconazole (Stiefel, a GSK company) was compared with itraconazole, miconazole and terbinafine in vitro and in vivo. A potent in vitro activity against Candida spp. (IC50 0.04-1.83 μM) and Microsporum and Trichophyton spp. (IC50 0.15-1.34 μM) was obtained, however, not against other filamentous moulds and zygomycetes. In the M. canis guinea pig model and C. albicans vulvovaginitis rat model, pramiconazole was superior to the reference compounds after oral and topical administration. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Antimicrobial agents and chemotherapy. - Washington, D.C., 1972, currens
| |
|
Publication
|
|
|
|
Washington, D.C.
:
American Society for Microbiology
,
2010
| |
|
ISSN
|
|
|
|
0066-4804
| |
|
Volume/pages
|
|
|
|
54
:11
(2010)
, p. 4927-4929
| |
|
ISI
|
|
|
|
000284155000060
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|